- News Home
17 April 2014 12:48 pm ,
Vol. 344 ,
Officials last week revealed that the U.S. contribution to ITER could cost $3.9 billion by 2034—roughly four times the...
An experimental hepatitis B drug that looked safe in animal trials tragically killed five of 15 patients in 1993. Now,...
Using the two high-quality genomes that exist for Neandertals and Denisovans, researchers find clues to gene activity...
A new report from the Intergovernmental Panel on Climate Change (IPCC) concludes that humanity has done little to slow...
Astronomers have discovered an Earth-sized planet in the habitable zone of a red dwarf—a star cooler than the sun—500...
Three years ago, Jennifer Francis of Rutgers University proposed that a warming Arctic was altering the behavior of the...
- 17 April 2014 12:48 pm , Vol. 344 , #6181
- About Us
Senate Panel Gives NIH $100 Million Boost for 2013
12 June 2012 5:40 pm
A Senate panel today approved a modest $100 million raise for the National Institutes of Health (NIH) in the 2013 fiscal year which begins on 1 October. The 0.3% bump to a total of $30.723 billion is slightly better than the president's request for no increase but disappointing to the research community.
Given fiscal pressures in Congress, "we're appreciative of any increase," says Jennifer Zeitzer, director of legislative relations for the Federation of American Societies for Experimental Biology. Still, she says, "It's going to be difficult for people in the research community. One-hundred-million dollars doesn't go very far."
The NIH budget is part of a broader spending bill approved today by the Senate appropriations subcommittee on labor, health and human services, and education. A summary of the bill also mentions NIH's Cures Acceleration Network. This drug development effort would receive $40 million, four times its current funding (but $10 million below the president's request).
The Senate vote would continue a trend of stagnation in NIH's budget, biomedical research advocates say. They argue that NIH spending in recent years has not kept pace with so-called "biomedical inflation"—the rate at which research costs escalate each year—and estimate that the agency's budget is effectively 17% below what it was a decade ago.
The full Senate Appropriations Committee is scheduled to vote on the bill on Thursday. At that point more detail on specific programs may become available.